Pregnenolone and depression: a brain signal, not proof of efficacy

Changing a brain measurement does not mean relieving depression. In a randomized trial in women with major depressive disorder, pregnenolone was associated with a change in resting-state connectivity. But the imaging analysis includes only 11 participants, and the available abstract reports no improvement in symptoms.

Illustration of the brain regions studied, the amygdala and frontal pole, without depicting individual results.
SupplementsEditorial illustration, not study data.

A crossover trial with two doses and a placebo

The study, conducted between 2019 and 2021, included 29 women with major depressive disorder, with a mean age of 45.6 years. In this crossover design, participants were randomized to receive oral pregnenolone at 500 mg per day, 800 mg per day, and a placebo in sequence.

Each condition lasted seven days, with a 14-day treatment-free interval between conditions. These doses describe the experiment and are not recommendations for use.

After each period, the researchers measured steroid concentrations and performed resting-state functional MRI. The connectivity analysis reported in the abstract involved a subgroup of 11 participants who had followed the protocol. The abstract does not explain why this analysis did not include all 29 women.

A difference at 500 mg, not at 800 mg

Compared with placebo, the 500 mg per day condition was associated with decreased functional connectivity between the bilateral amygdala and the left frontal pole. This measurement describes the relationship between fluctuations in the activity of brain regions at rest, not the severity of depressive symptoms directly.

At 800 mg per day, the difference in connectivity compared with placebo was not statistically significant. Blood concentrations of allopregnanolone, however, increased with both doses compared with placebo.

The authors suggest an inverted-U response, in which an intermediate dose might engage certain circuits more than a higher dose. This remains a hypothesis: a significant result at one dose and a nonsignificant result at the other are not enough, on their own, to establish an optimal dose.

What this finding cannot tell us

The finding concerns an imaging marker, not a demonstrated clinical benefit. The provided abstract reports no reduction in symptoms, remission rates, or improvement in daily functioning. It therefore does not support the conclusion that pregnenolone treats depression.

The sample analyzed is small, and each exposure lasts only seven days. These data also do not allow the finding to be extended to men, people without depression, or long-term use.

Finally, the abstract does not detail adverse effects, interactions, or contraindications. A measurable change in the brain is therefore not sufficient grounds to start supplementation.

Limitations to keep in mind

PubMed abstract only; full text not reviewed. Imaging analysis limited to 11 participants out of 29 enrolled, seven-day exposures, and no clinical outcomes reported in the abstract. Tolerability, funding, and conflicts of interest not verified.

What we can take away

This study suggests an effect of pregnenolone on a measure of brain connectivity in some women with depression. It establishes neither antidepressant efficacy nor a dose to use.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.